The Registry of Toxic Effects of Chemical Substances
2 - Oxetanone |
UPDATE: May 2005 | MW: 72.07 | MF: C3H4O2 |
SYNONYMS:
|
|
|
SKIN AND EYE IRRITATION DATA AND REFERENCES:
ROUTE/ | ORGANISM
DOSE
|
| EFFECT
REFERENCE
|
N/R |
N/R
|
N/R
|
N/R
|
|
MUTATION DATA AND REFERENCES:
SYSTEM TEST
|
ROUTE/ | ORGANISM/ TISSUE
DOSE
|
REFERENCE
|
cytogenetic analysis
|
hamster
fibroblast
|
30 mg/L/24 hour
|
MUREAV 48,337,1977
|
cytogenetic analysis
|
hamster
lung
|
18 mg/L
|
GMCRDC 27,95,1981
|
cytogenetic analysis
|
hamster
ovary
|
200 µg/L
|
ENMUDM 7,1,1985
|
cytogenetic analysis
|
human
fibroblast
|
13 mg/L
|
CNREA8 46,4720,1986
|
cytogenetic analysis
|
human
HeLa cell
|
100 nmol/L
|
TXCYAC 9,21,1978
|
cytogenetic analysis
|
rat
leukocyte
|
250 µmol/L/5 hour
|
LBANAX 3,157,1969
|
DNA adduct
|
Escherichia coli
|
10 µmol/L
|
MUREAV 89,95,1981
|
DNA adduct
|
mammal (species unspecified)
lymphocyte
|
1,600 µmol/L/20 hour
|
CBINA8 18,327,1977
|
DNA adduct
|
mouse
liver
|
1,600 µmol/L/20 hour
|
CBINA8 18,327,1977
|
DNA damage
|
Bacillus subtilis
|
110 nmol/L
|
CNREA8 41,4368,1981
|
DNA damage
|
hamster
lung
|
100 µmol/L/1 hour
|
BBRCA9 72,732,1976
|
DNA damage
|
hamster
embryo
|
2,500 µg/L
|
CBINA8 13,105,1976
|
DNA damage
|
human
lymphocyte
|
1 mmol/L
|
JACTDZ 1(3),125,1982
|
DNA damage
|
skin | mouse
8 nmol/kg
|
ANYAA9 163,751,1969
|
DNA damage
|
mouse
Ascites tumor
|
12 mmol/L
|
CNREA8 36,3025,1976
|
DNA damage
|
intraperitoneal | mouse
100 mg/kg
|
MUREAV 493,39,2001
|
DNA damage
|
oral | mouse
150 mg/kg
|
MUREAV 493,39,2001
|
DNA damage
|
other microorganisms
|
10 mmol/L
|
JGAMA9 19,339,1973
|
DNA damage
|
other microorganisms
|
1,000 ppm
|
CBINA8 10,41,1975
|
DNA damage
|
other microorganisms
|
2 pph
|
CBINA8 10,41,1975
|
DNA damage
|
other microorganisms
|
1,600 µmol/L
|
PNASA6 73,2629,1976
|
DNA damage
|
rat
liver
|
30 µmol/L
|
MUREAV 368,59,1996
|
DNA damage
|
oral | rat
100 mg/kg
|
CNREA8 38,1589,1978
|
DNA inhibition
|
human
HeLa cell
|
500 µmol/L
|
MUREAV 92,427,1982
|
DNA inhibition
|
skin | mouse
8,600 µmol/kg
|
CNREA8 33,769,1973
|
DNA inhibition
|
other microorganisms
|
5 mmol/L
|
JGAMA9 19,339,1973
|
DNA repair
|
Escherichia coli
|
10 µg/disc
|
JJIND8 62,873,1979
|
unscheduled DNA synthesis
|
Escherichia coli
|
15 mmol/L
|
ZKKOBW 92,177,1978
|
unscheduled DNA synthesis
|
human
fibroblast
|
160 µg/L
|
TXCYAC 21,151,1981
|
unscheduled DNA synthesis
|
skin | mouse
8,600 µmol/kg
|
CNREA8 33,769,1973
|
unscheduled DNA synthesis
|
mouse
other cell types
|
500 µmol/L
|
JIDEAE 62,480,1974
|
unscheduled DNA synthesis
|
mouse
fibroblast
|
500 µmol/L
|
JIDEAE 62,480,1974
|
host-mediated assay
|
mouse
| Salmonella typhimurium
405 mg/kg
|
JJIND8 62,911,1979
|
mutation in microorganisms
|
Escherichia coli
|
1 µL/plate (+/-enzymatic activation step)
|
PMRSDJ 1,387,1981
|
mutation in microorganisms
|
mouse
lymphocyte
|
15 mg/L/4 hour (+enzymatic activation step)
|
MUREAV 59,61,1979
|
mutation in microorganisms
|
Neurospora crassa
|
2 µg/plate (-enzymatic activation step)
|
MUREAV 53,297,1978
|
mutation in microorganisms
|
other microorganisms
|
2 gm/L (-enzymatic activation step)
|
MOPMA3 6,667,1970
|
mutation in microorganisms
|
other microorganisms
|
450 µmol/L (-enzymatic activation step)
|
CNREA8 42,3480,1982
|
mutation in microorganisms
|
other microorganisms
|
667 ppm/1 hour (-enzymatic activation step)
|
MUREAV 34,175,1976
|
mutation in microorganisms
|
Salmonella typhimurium
|
1 µg/plate (+enzymatic activation step)
|
ENMUDM 5(Suppl 1),3,1983
|
mutation in microorganisms
|
Saccharomyes cerevisiae
|
89 mg/L (+/-enzymatic activation step)
|
PMRSDJ 1,414,1981
|
mutation in microorganisms
|
Serratia marcescens
|
2 gm/L (-enzymatic activation step)
|
ATXKA8 28,93,1971
|
mutation in microorganisms
|
Schizosaccharomyces pombe
|
100 µg/L (+/-enzymatic activation step)
|
PMRSDJ 1,424,1981
|
micronucleus test
|
intraperitoneal | mouse
54 mg/kg/24 hour- continuous
|
MUREAV 216,321,1989
|
gene conversion and mitotic recombination
|
Saccharomyes cerevisiae
|
1 µg/plate
|
PMRSDJ 1,456,1981
|
mutation in mammalian somatic cells
|
hamster
ovary
|
10 mg/L
|
MUREAV 94,449,1982
|
mutation in mammalian somatic cells
|
hamster
lung
|
2 mmol/L
|
ENMUDM 6,426,1984
|
mutation in mammalian somatic cells
|
mouse
lymphocyte
|
2 mg/L/2 hour
|
MUREAV 59,61,1979
|
morphological transform
|
intraperitoneal | hamster
250 mg/kg
|
ARPAAQ 95,380,1973
|
morphological transform
|
hamster
embryo
|
2,500 µg/L
|
CBINA8 13,105,1976
|
morphological transform
|
hamster
kidney
|
80 µg/L
|
BJCAAI 37,873,1978
|
morphological transform
|
human
other cell types
|
7,500 µg/L
|
CNREA8 41,5096,1981
|
morphological transform
|
human
fibroblast
|
28 µmol/L
|
PNASA6 80,7219,1983
|
morphological transform
|
mouse
embryo
|
100 µg/L
|
PMRSDJ 5,659,1985
|
other mutation test systems
|
Bacillus subtilis
|
50 mmol/L
|
JOBAAY 136,854,1978
|
other mutation test systems
|
mouse
other cell types
|
57 gm/L
|
BCPCA6 23,937,1974
|
other mutation test systems
|
other microorganisms
|
5 mmol/L
|
JGAMA9 19,339,1973
|
other mutation test systems
|
Salmonella typhimurium
|
8,300 µg/L
|
MUREAV 192,239,1987
|
phage inhibition capacity
|
Escherichia coli
|
340 nmol/plate
|
PNASA6 79,5971,1982
|
phage inhibition capacity
|
other microorganisms
|
1 mg/plate
|
ZMMPAO 231,369,1975
|
phage inhibition capacity
|
Salmonella typhimurium
|
500 ppm
|
CNREA8 30,830,1970
|
sister chromatid exchange
|
hamster
ovary
|
100 µmol/L
|
NATUAS 258,121,1975
|
sister chromatid exchange
|
hamster
lung
|
100 µmol/L
|
MUREAV 118,103,1983
|
sex chromosome loss and nondisjunction
|
oral | Drosophila melanogaster
250 ppm
|
ENMUDM 6,189,1984
|
sex chromosome loss and nondisjunction
|
parenteral | Drosophila melanogaster
10 mmol/L
|
MUREAV 66,55,1979
|
sex chromosome loss and nondisjunction
|
Saccharomyes cerevisiae
|
25 mg/L
|
PMRSDJ 1,468,1981
|
specific locus test
|
oral | Drosophila melanogaster
200 mmol/L
|
ENMUDM 6,153,1984
|
heritable translocation test
|
parenteral | Drosophila melanogaster
25 mmol/L
|
MUREAV 66,55,1979
|
|
REPRODUCTIVE EFFECTS DATA AND REFERENCES:
ROUTE/ | ORGANISM
DOSE
|
| EFFECT
REFERENCE
|
N/R |
N/R
|
N/R
|
N/R
|
|
TUMORIGENIC DATA AND REFERENCES:
ROUTE/ | ORGANISM
DOSE
|
| EFFECT
REFERENCE
|
inhalation | rat
lowest published toxic concentration: 5 ppm/6 hour/30 day- intermittent
|
Tumorigenic: Carcinogenic by RTECS criteria | Olfaction: Tumors
JJIND8 79,285,1987
|
intratracheal | rat
lowest published toxic dose: 72 mg/kg/30 week- intermittent
|
Tumorigenic: Equivocal tumorigenic agent by RTECS criteria | Lung, Thorax, or Respiration: Tumors Lung, Thorax, or Respiration: Bronchogenic carcinoma
BJCAAI 20,134,1966
|
intravenous | mouse
lowest published toxic dose: 40 mg/kg
|
Tumorigenic: Equivocal tumorigenic agent by RTECS criteria | Skin and Appendages: Tumors Tumorigenic: Tumors at site of application
BJCAAI 10,357,1956
|
oral | mouse
lowest published toxic dose: 3,080 mg/kg/77 week- intermittent
|
Tumorigenic: Carcinogenic by RTECS criteria | Gastrointestinal: Tumors
JJIND8 63,1433,1979
|
oral | mouse
toxic dose : 320 mg/kg/8 week- intermittent
|
Tumorigenic: Equivocal tumorigenic agent by RTECS criteria | Gastrointestinal: Tumors
CNREA8 43,4747,1983
|
oral | rat
lowest published toxic dose: 2,868 mg/kg/1 year- intermittent
|
Tumorigenic: Carcinogenic by RTECS criteria | Gastrointestinal: Tumors Liver: Tumors
BJCAAI 46,924,1982
|
oral | rat
toxic dose : 3,050 mg/kg/61 week- intermittent
|
Tumorigenic: Equivocal tumorigenic agent by RTECS criteria | Gastrointestinal: Tumors
JNCIAM 37,825,1966
|
rectal | rat
lowest published toxic dose: 857 mg/kg/6 week- intermittent
|
Tumorigenic: Equivocal tumorigenic agent by RTECS criteria | Gastrointestinal: Colon tumors
CNREA8 48,2740,1988
|
subcutaneous | mouse
lowest published toxic dose: 69 mg/kg/43 week- intermittent
|
Tumorigenic: Neoplastic by RTECS criteria | Tumorigenic: Tumors at site of application
BJCAAI 19,392,1965
|
subcutaneous | mouse
toxic dose : 648 mg/kg/54 week- intermittent
|
Tumorigenic: Neoplastic by RTECS criteria | Tumorigenic: Tumors at site of application
JJIND8 63,1433,1979
|
subcutaneous | mouse
toxic dose : 408 mg/kg/34 week- intermittent
|
Tumorigenic: Neoplastic by RTECS criteria | Tumorigenic: Tumors at site of application
JNCIAM 53,695,1974
|
subcutaneous | mouse
toxic dose : 1,168 mg/kg/40 week- intermittent
|
Tumorigenic: Neoplastic by RTECS criteria | Tumorigenic: Tumors at site of application
JNCIAM 37,825,1966
|
subcutaneous | rat
lowest published toxic dose: 22 mg/kg/25 week- intermittent
|
Tumorigenic: Carcinogenic by RTECS criteria | Tumorigenic: Tumors at site of application
BMBUAQ 20,96,1964
|
subcutaneous | rat
toxic dose : 50 mg/kg/25 week- intermittent
|
Tumorigenic: Neoplastic by RTECS criteria | Tumorigenic: Tumors at site of application
BJCAAI 15,85,1961
|
subcutaneous | rat
toxic dose : 1,080 mg/kg/54 week- intermittent
|
Tumorigenic: Carcinogenic by RTECS criteria | Tumorigenic: Tumors at site of application
JNCIAM 39,1213,1967
|
skin | guinea pig
lowest published toxic dose: 56 mg/kg/141 week- intermittent
|
Tumorigenic: Equivocal tumorigenic agent by RTECS criteria | Liver: Tumors Skin and Appendages: Tumors
BJCAAI 20,200,1966
|
skin | mouse
lowest published toxic dose: 6,200 mg/kg/15 week- intermittent
|
Tumorigenic: Carcinogenic by RTECS criteria | Skin and Appendages: Tumors
BJCAAI 9,177,1955
|
skin | mouse
toxic dose : 8,100 mg/kg/27 week- intermittent
|
Tumorigenic: Equivocal tumorigenic agent by RTECS criteria | Endocrine: Tumors Skin and Appendages: Tumors
BJCAAI 10,357,1956
|
skin | mouse
toxic dose : 11 gm/kg/56 week- intermittent
|
Tumorigenic: Carcinogenic by RTECS criteria | Skin and Appendages: Tumors Tumorigenic: Tumors at site of application
TXCYAC 6,139,1976
|
skin | mouse
toxic dose : 37,772 mg/kg/2 year- intermittent
|
Tumorigenic: Carcinogenic by RTECS criteria | Skin and Appendages: Tumors Tumorigenic: Tumors at site of application
FCTOD7 23,1081,1985
|
|
ACUTE TOXICITY DATA AND REFERENCES:
ROUTE/ | ORGANISM
DOSE
|
| EFFECT
REFERENCE
|
inhalation | rat
lethal concentration (50 percent kill): 25 ppm/6 hour
|
N/R
|
85INA8 5,497,1986
|
intraperitoneal | mouse
lethal dose (50 percent kill): 405 mg/kg
|
N/R
|
JJIND8 62,911,1979
|
|
OTHER MULTIPLE DOSE DATA AND REFERENCES:
ROUTE/ | ORGANISM
DOSE
|
| EFFECT
REFERENCE
|
N/R |
N/R
|
N/R
|
N/R
|
|
REVIEWS:
ORGANIZATION
|
STANDARD
|
|
REFERENCE
American Conference of Governmental Industrial Hygienists (ACGIH) Threshold Limit Value
|
time-weighted average 0.5 ppm
|
DTLVS* TLV/BEI,2003
|
American Conference of Governmental Industrial Hygienists (ACGIH) Threshold Limit Value
|
Confirmed Animal Carcinogen with Unknown
|
DTLVS* TLV/BEI,2003
|
International Agency for Research on Cancer (IARC) Cancer Review
|
Animal Sufficient Evidence
|
IMEMDT 4,259,1974
|
International Agency for Research on Cancer (IARC) Cancer Review
|
Animal Sufficient Evidence
|
IMEMDT 71,1103,1999
|
International Agency for Research on Cancer (IARC) Cancer Review
|
Human No Adequate Data
|
IMEMDT 4,259,1974
|
International Agency for Research on Cancer (IARC) Cancer Review
|
Human No Adequate Data
|
IMEMDT 71,1103,1999
|
International Agency for Research on Cancer (IARC) Cancer Review
|
Group 2B
|
IMEMDT 71,1103,1999
|
TOXICOLOGY REVIEW
|
|
ENVRAL 7,243,1974
|
TOXICOLOGY REVIEW
|
|
22HAAD 6,409,1971
|
|
STANDARDS AND REGULATIONS:
ORGANIZATION
|
STANDARD
|
|
REFERENCE
Mine Safety and Health Administration (MSHA) STANDARD
|
SUSPECTED CARCINOGEN
|
DTLWS* 3,27,1972
|
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Construction)
|
see Code of Federal Regulations (CFR) 29,1926.1113
|
CFRGBR 29,1926.55,1994
|
Occupational Safety and Health Administration (OSHA)
|
cancer suspect agent
|
CFRGBR 29,1910.1013,1987
|
Occupational Exposure Limit - AUSTRALIA
|
time-weighted average 0.5 ppm (1.5 mg/m3), Carcinogen, JAN1993
|
Occupational Exposure Limit - AUSTRIA
|
Carcinogen, JAN1999
|
Occupational Exposure Limit - BELGIUM
|
time-weighted average 0.5 ppm (1.5 mg/m3), Carcinogen, JAN1993
|
Occupational Exposure Limit - DENMARK
|
time-weighted average 0.1 ppm (1.5 mg/m3), JAN1999
|
Occupational Exposure Limit - FINLAND
|
Carcinogen, JAN1999
|
Occupational Exposure Limit - FRANCE
|
Carcinogen, JAN1993
|
Occupational Exposure Limit - GERMANY
|
Carcinogen, JAN1999
|
Occupational Exposure Limit - POLAND
|
MAC(time-weighted average) 1 mg/m3, JAN1999
|
Occupational Exposure Limit - SWEDEN
|
Carcinogen, JAN1999
|
Occupational Exposure Limit - SWITZERLAND
|
MAK- week 0.5 ppm (1.5 mg/m3), Carcinogen, JAN1999
|
Occupational Exposure Limit - UNITED KINGDOM
|
Carcinogen, SEP2000
|
Occupational Exposure Limit IN ARGENTINA, BULGARIA, COLOMBIA, JORDAN, KOREA
|
American Conference of Governmental Industrial Hygienists (ACGIH) Threshold Limit Value; | Confirmed Animal Carcinogen with Unknown
Occupational Exposure Limit IN NEW ZEALAND, SINGAPORE, VIETNAM
|
American Conference of Governmental Industrial Hygienists (ACGIH) Threshold Limit Value |
Confirmed Animal Carcinogen with Unknown |
NIOSH DOCUMENTATION AND SURVEILLANCE:
ORGANIZATION
|
STANDARD or SURVEY
|
|
REFERENCE
National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO beta-PROPIOLACTONE-air
|
Carcinogen use 29 Code of Federal Regulations (CFR) 1910.1013
|
NIOSH* DHHS #92-100,1992
|
National Occupational Hazard Survey 1974
|
National Occupational Hazard Survey 1974: Hazard Code: 62270; |
Number of Industries 1; Total Number of Facilities 19; Number of Occupations 1; Total Number of Employees Exposed 38 |
STATUS IN FEDERAL AGENCIES:
ORGANIZATION
|
|
REFERENCE
EPA GENETOX PROGRAM 1988, Positive: Carcinogenicity-mouse/rat; SHE-focus assay
|
EPA GENETOX PROGRAM 1988, Positive: Cell transform.-SA7/SHE
|
EPA GENETOX PROGRAM 1988, Positive: D melanogaster-reciprocal translocation
|
EPA GENETOX PROGRAM 1988, Positive: Host-mediated assay; L5178Y cells in vitro-TK test
|
EPA GENETOX PROGRAM 1988, Positive: N crassa-forward mutation; N crassa-reversion
|
EPA GENETOX PROGRAM 1988, Positive: E coli polA without S9; Histidine reversion-Ames test
|
EPA GENETOX PROGRAM 1988, Positive: D melanogaster Sex-linked lethal
|
EPA GENETOX PROGRAM 1988, Positive: In vitro UDS-human fibroblast
|
EPA GENETOX PROGRAM 1988, Positive: S cerevisiae gene conversion; S cerevisiae-homozygosis
|
EPA GENETOX PROGRAM 1988, Positive: S cerevisiae-reversion
|
EPA GENETOX PROGRAM 1988, Positive/dose response: In vitro SCE-nonhuman
|
EPA GENETOX PROGRAM 1988, Negative: Sperm morphology-mouse
|
EPA GENETOX PROGRAM 1988, Inconclusive: Mammalian micronucleus
|
EPA GENETOX PROGRAM 1988, Positive: CHO gene mutation
|
EPA TSCA Section 8(b) CHEMICAL INVENTORY
|
Used as an intermediate in the production of acrylic acids and esters
|
Used as a vapor sterilant, vapor phase disinfectant and in organic synthesis
|
On EPA IRIS database
|
EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001
|
NTP 11th Report on Carcinogens,2004:Reasonably anticipated to be a human carcinogen
|
|
REFERENCES:
CODEN
|
|
REFERENCE
22HAAD
|
"Microbial Toxins, 1970-72," Ajil, S.J., et al., eds., New York, Academic Press, Inc., 1970-72
|
85INA8
|
"Documentation of the Threshold Limit Values and Biological Exposure Indices," 5th ed.,
Cincinnati, OH, American Conference of Governmental Industrial Hygienists, Inc., 1986
|
ANYAA9
|
Annals of the New York Academy of Sciences. (New York Academy of Sciences, 2 E. 63rd St., New
York, NY 10021) V.1- 1877-
|
ARPAAQ
|
Archives of Pathology. (Chicago, IL) V.5(3)-50(3), 1928-50; V.70-99, 1960-75. For publisher
information, see APLMAS.
|
ATXKA8
|
Archiv fuer Toxikologie. (Berlin, Fed. Rep. Ger.) V.15-31, 1954-74. For publisher
information, see ARTODN.
|
BBRCA9
|
Biochemical and Biophysical Research Communications. (Academic Press, Inc., 1 E. First St.,
Duluth, MN 55802) V.1- 1959-
|
BCPCA6
|
Biochemical Pharmacology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY
10523) V.1- 1958-
|
BJCAAI
|
British Journal of Cancer. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS,
UK) V.1- 1947-
|
BMBUAQ
|
British Medical Bulletin. (Longman Group UK Ltd., Longman House, Burnt Mill, Harlow, Essex
CM20 2JE, UK) V.1- 1943-
|
CBINA8
|
Chemico-Biological Interactions. (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick,
Ireland) V.1- 1969-
|
CFRGBR
|
Code of Federal Regulations. (U.S. Government Printing Office, Supt. of Documents,
Washington, DC 20402)
|
CNREA8
|
Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA
19106) V.1- 1941-
|
DTLVS*
|
The Threshold Limit Values (TLVs) and Biological Exposure Indices (BEIs) booklet issues by
American Conference of Governmental Industrial Hygienists (ACGIH), Cincinnati, OH, 1996
|
DTLWS*
|
"Documentation of the Threshold Limit Values for Substances in Workroom Air," Supplements. For
publisher information, see 85INA8.
|
ENMUDM
|
Environmental Mutagenesis. (New York, NY) V.1-9, 1979-87. For publisher information, see
EMMUEG.
|
ENVRAL
|
Environmental Research. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1-
1967-
|
FCTOD7
|
Food and Chemical Toxicology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford,
NY 10523) V.20- 1982-
|
GMCRDC
|
Gann Monograph on Cancer Research. (Plenum Pub. Corp., 233 Spring St., New York, NY 10013)
No. 11- 1971-
|
IMEMDT
|
IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications
Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972-
|
JACTDZ
|
Journal of the American College of Toxicology. (Mary Ann Liebert, Inc., 1651 Third Ave., New
York, NY 10128) V.1-12, 1982-1993. Discontinued.
|
JGAMA9
|
Journal of General and Applied Microbiology. (Microbiology Research Foundation, c/o Japan
Academic Soc. Center Bldg., 2-4-16 Yayoi, Bunkyo-ku, Tokyo, 113, Japan) V.1- 1955-
|
JIDEAE
|
Journal of Investigative Dermatology. (Williams & Wilkins Co., 428 E. Preston St., Baltimore,
MD 21202) V.1- 1938-
|
JJIND8
|
JNCI, Journal of the National Cancer Institute. (Washington, DC) V.61-79, 1978-87. For
publisher information, see JNCIEQ.
|
JNCIAM
|
Journal of the National Cancer Institute. (Washington, DC) V.1-60, 1940-78. For publisher
information, see JJIND8.
|
JOBAAY
|
Journal of Bacteriology. (American Soc. for Microbiology, 1913 I St., NW, Washington, DC
20006) V.1- 1916-
|
LBANAX
|
Laboratory Animals. (Laboratory Animals Ltd., 1 Thrifts Mead, Theydon Bois, Essex CM16 7NF,
UK) V.1- 1967-
|
MOPMA3
|
Molecular Pharmacology. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202)
V.1- 1965-
|
MUREAV
|
Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1-
1964-
|
NATUAS
|
Nature. (Nature Subscription Dept., POB 1018, Manasguan, NJ 08736) V.1- 1869-
|
NIOSH*
|
National Institute of Occupational Safety and Health, U.S. Dept. of Health, Education, and
Welfare, Reports and Memoranda.
|
PMRSDJ
|
Progress in Mutation Research. (Elsevier Science Pub. Co., Inc., 52 Vanderbilt Ave., New
York, NY 10017) V.1- 1981-
|
PNASA6
|
Proceedings of the National Academy of Sciences of the United States of America. (National
Academy of Sciences, Printing & Pub. Office, 2101 Constitution Ave., Washington, DC 20418)
V.1- 1915-
|
TXCYAC
|
Toxicology. (Elsevier Scientific Pub. Ireland, Ltd., POB 85, Limerick, Ireland) V.1- 1973-
|
ZKKOBW
|
Zeitschrift fuer Krebsforschung und Klinische Onkologie. (Berlin, Fed. Rep. Ger.) V.76-92,
1971-78. For publisher information, see JCROD7.
|
ZMMPAO
|
Zentralblatt fuer Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene, Abteilung
1: Originale, Reihe A: Medizinische Mikrobiologie und Parasitologie. (Stuttgart, Fed. Rep.
Ger.) V.217-245, 1971-79.
|
|